coagulation factor XIII A chain
Zuletzt aktualisiert 18. Aug 2020
Erfüllt die redaktionelle Richtlinien
- HerunterladenHerunterladen
- Teilen
- Language
- Diskussion
- Audio-Version
- Zu bevorzugten Quellen bei Google hinzufügen
Der F13A1 gene provides instructions for making one part, the A subunit, of a protein called factor XIII. This protein is part of a group of related proteins called coagulation factors that are essential for normal blood clotting. They work together as part of the coagulation cascade, which is a series of chemical reactions that forms blood clots in response to injury. After an injury, clots seal off blood vessels to stop bleeding and trigger blood vessel repair. Factor XIII acts at the end of the cascade to strengthen and stabilize newly formed clots, preventing further blood loss.
Normal function
Der F13A1 gene provides instructions for making one part, the A subunit, of a protein called factor XIII. This protein is part of a group of related proteins called coagulation factors that are essential for normal blood clotting. They work together as part of the coagulation cascade, which is a series of chemical reactions that forms blood clots in response to injury. After an injury, clots seal off blood vessels to stop bleeding and trigger blood vessel repair. Factor XIII acts at the end of the cascade to strengthen and stabilize newly formed clots, preventing further blood loss.
Factor XIII in the bloodstream is made of two A subunits (produced from the F13A1 gene) and two B subunits (produced from the F13B gene). When a new blood clot forms, the A and B subunits separate from one another, and the A subunit is cut (cleaved) to produce the active form of factor XIII (factor XIIIa). The active protein links together molecules of fibrin, the material that forms the clot, which strengthens the clot and keeps other molecules from breaking it down.
Studies suggest that factor XIII has additional functions, although these are less well understood than its role in blood clotting. Specifically, factor XIII is likely involved in other aspects of wound healing, immune system function, maintaining pregnancy, bone formation, and the growth of new blood vessels (angiogenesis).
Conditions referring to this gene or chromosome
Other names
bA525O21.1 (coagulation factor XIII, A1 polypeptide)
coagulation factor XIII A chain precursor
coagulation factor XIII, A polypeptide
coagulation factor XIII, A1 polypeptide
coagulation factor XIIIa
F13A
factor XIIIa
fibrin stabilizing factor, A subunit
fibrinoligase
FSF, A subunit
protein-glutamine gamma-glutamyltransferase A chain
TGase
transglutaminase A chain
transglutaminase. plasma
Related patient information and medicines
Patient information leaflet
Blutgerinnungstests
Blutgerinnungstests are used to diagnose and assess bleeding problems and to monitor people who take Warfarin or other Antikoagulans medicines. You may be advi... These chemicals then react with other chemicals and proteins in the plasma, called clotting factors. There are 13 known clotting factors which are called by their Roman numbers - factor.
Patient information leaflet
Antikoagulantien
How do anticoagulants work. Our blood has a complex system of chemicals in it, which, when activated, cause blood clots to form. These activated platelets and the damaged tissue release chemicals which react with other chemicals and proteins in the blood, called clotting factors. There are 13 known clotting factors which are called by their Roman.
Patient information leaflet
Antiphospholipid-Syndrom
It is a disease that affects the blood and makes it more likely to clot than normal - a thrombophilia. The presence of the antiphospholipid antibodies causes the increased tendency of the blood to clot - they can trigger the coagulation cascade. The coagulation cascade is a chain reaction of events or chemical reactions that occur in the blood,.
Patient information leaflet
Thrombophilie
The body has a natural clotting process in the blood, which is altered in thrombophilia. Thrombophilie refers to a group of conditions where the Blutgerinnsel more easily than normal. The body has a natural clotting process in the bl... When a blood vessel is injured, the clotting process is triggered. It is a chain reaction of different chemicals.
Patient information leaflet
Barrett-Ösophagus
The coil then emits heat energy which destroys the abnormal cells. Nearby normal cells then multiply and replace the destroyed abnormal cells. Argon plasma coagulation This treatment uses a jet of argon gas, together with an electric current, to burn away dysplastic cells. Endoscopic mucosal resection (EMR) This is a procedure that is done via.
Patient information leaflet
Kann ich Apixaban und Rybelsus zusammen einnehmen?
There ... These two medicines work in different ways and do not typically interfere with how the other is absorbed, broken down, or removed from the body. Why this happens Apixaban ist an anticoagulant (blood thinner) that works by blocking a clotting factor genannt Factor Xa. Rybelsus is a GLP-1 receptor agonist used for type 2 diabetes that mimics.
Weiterführende Lektüre und Referenzen
- coagulation factor XIII A chain; MedlinePlus, National Library of Medicine.
- Bagoly Z, Koncz Z, Harsfalvi J, Muszbek L. Factor XIII, clot structure, thrombosis. Thromb Res. 2012 Mar;129(3):382-7. doi: 10.1016/j.thromres.2011.11.040. Epub 2011 Dec 24.
- Biswas A, Ivaskevicius V, Seitz R, Thomas A, Oldenburg J. An update of the mutation profile of Factor 13 A and B genes. Blood Rev. 2011 Sep;25(5):193-204. doi: 10.1016/j.blre.2011.03.001. Epub 2011 Jun 2.
- Biswas A, Ivaskevicius V, Thomas A, Oldenburg J. Coagulation factor XIII deficiency. Diagnosis, prevalence and management of inherited and acquired forms. Hamostaseologie. 2014;34(2):160-6. doi: 10.5482/HAMO-13-08-0046. Epub 2014 Feb 7.
- Hethershaw EL, Cilia La Corte AL, Duval C, Ali M, Grant PJ, Ariens RA, Philippou H. The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis. J Thromb Haemost. 2014 Feb;12(2):197-205. doi: 10.1111/jth.12455.
- Levy JH, Greenberg C. Biology of Factor XIII and clinical manifestations of Factor XIII deficiency. Transfusion. 2013 May;53(5):1120-31. doi: 10.1111/j.1537-2995.2012.03865.x. Epub 2012 Aug 28.
- Muszbek L, Bereczky Z, Bagoly Z, Komaromi I, Katona E. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev. 2011 Jul;91(3):931-72. doi: 10.1152/physrev.00016.2010.
- Schroeder V, Kohler HP. Factor XIII deficiency: an update. Semin Thromb Hemost. 2013 Sep;39(6):632-41. doi: 10.1055/s-0033-1353392. Epub 2013 Aug 8.
Artikelverlauf
Artikel auch verfügbar in Englisch, Deutsch, Spanisch, Französisch, Italienisch, Portugiesisch, Hindi, Hebräisch, Arabisch, und Schwedisch.
18. Aug 2020 | Neueste Version
1 Aug 2015 | Ursprünglich veröffentlicht
Nehmen Sie an der Diskussion teil
Teilen Sie Ihre Gedanken oder Erfahrungen mit anderen in unserem Patientengemeinschaften.
Fragen, teilen, verbinden.
Durchsuchen Sie Diskussionen, stellen Sie Fragen und teilen Sie Erfahrungen zu Hunderten von Gesundheitsthemen.
Abonnieren Sie den Patienten-Newsletter
Ihre wöchentliche Dosis klarer, vertrauenswürdiger Gesundheitsberatung - geschrieben, um Ihnen zu helfen, sich informiert, selbstbewusst und in Kontrolle zu fühlen.
Durch das Abonnieren akzeptieren Sie unsere Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.